Biotech, Food, Drug

The food we eat and the medicine we put into our bodies are highly regulated by a variety of government agencies. In the United States by the Food and Drug Administration (FDA) and the United States Department of Agriculture (USDA) regulate the processes by which food makes its way to the grocery store and medicine is approved for consumer use.  As the science grows more complex behind the pharmaceutical and food industry, interpretation of the regulations in place is becoming more nuanced.  Overseas, these industries are regulated by a variety of agencies; for example, the Minister of Agriculture in Canada, Centre for Food Safety in Hong Kong, and the Committee of Environmental, Public Health and Food Safety (EU), are among the many governing-bodies which regulate biotechnology, food, and drugs throughout the world.

The National Law Review is your free online resource to agency news, emerging topics in food and drug, and the latest in biotechnology updates. From nanotechnologies being used in research, to regulations of imported foods coming into the US from overseas or the development of medical devices and drugs, readers can find expert legal analysis of the developments in the industry, as well as reports on changes within the agencies that regulate these industries. The National Law Review also covers topics related to licensing, Food Safety and Inspection Services (FSIS), food and beverage regulation in the US and worldwide, nutrition labeling, and country of origin labeling guidelines.

With recent legislation being passed throughout the US in relation to marijuana use, both for recreational and medicinal purposes, readers will also find up-to-date information, litigation, and news coming from this area of interest as well. Regulations in California for labeling and proper sales of marijuana, to use in different states, or internationally, as well as rules for promoting and advertising marijuana are also covered on the site. Additionally, the development and changing landscape of tobacco use to include vaping, and how e-cigarettes and vaping are regulated, is also covered by NLR authors.

Readers who are interested in food safety, inspection, imports into the US, and regulations, these topics are covered regularly on The National Law Review as well. New legislation from the FDA, USDA, Department of Agriculture, and international bodies, are covered on the site. If you are looking for details on new nutrition-labeling regulations or health risks of consuming certain imported foods, you will find these topics, and many more, on The National Law Review.

For hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis Twitter feed, and sign up for complimentary e-news bulletins.

Custom text Title Organization Sort ascending
May
12
2021
Health Law Diagnosed — Hot Topics in FDA Regulation and Enforcement [PODCAST] Mintz
Apr
9
2013
Energy & Environmental Law Update April 8, 2013 Mintz
May
15
2018
ML Strategies Health Care Preview – May 14, 2018 Mintz
Aug
28
2013
Energy and Environment Law Update - August 26, 2013 Mintz
Sep
4
2018
CA Prop 65 Coffee Issues Still Brewing Mintz
Jan
22
2014
Energy & Environmental Law Update - Week of January 21, 2014 Mintz
Mar
26
2014
Examples of 2014 DOE (Department of Energy) Grants, Loan and Financing Programs – Part 2 of 3 Mintz
Apr
2
2014
Examples of 2014 Department of Energy (DOE) Grants, Loan and Financing Programs – Part 3 of 3 Mintz
Apr
29
2014
Energy and Environmental Law Update - April 28, 2014 Mintz
Jun
18
2014
Grocery Manufacturers File Suit Against Vermont Over Genetically Modified Organisms (GMO) Law Mintz
Feb
11
2019
45 States Now Have Biosimilar Substitution Laws Mintz
Feb
27
2019
ML Strategies Health Care Preview FEBRUARY 25, 2019 Mintz
Mar
4
2019
Five Takeaways from the Senate Finance Committee’s Hearing on Drug Pricing Mintz
Sep
3
2014
Government Issues New Rules for Religious Employers, But Health Plans, Third Party Administrators (TPAs), and Pharmacy Benefits Managers (PBMs) are still on the Hook to Provide Contraceptive Coverage Mintz
Apr
29
2019
Update on FDA’s Comprehensive Regenerative Medicine Policies and Enforcement Activities Mintz
Nov
7
2014
November Elections Impact the Food & Beverage Industry (Part 1) Mintz
May
9
2019
CMS Finalizes Rule Requiring Disclosure of Drug Prices in TV Ads Mintz
Dec
4
2014
Group Purchasing Organization (GPO) Fees Under Scrutiny by the GAO (Government Accountability Office) Mintz
Feb
25
2015
The Court’s Decision in the FLANAX US Trademark Dispute Gives Bayer a Headache Mintz
Sep
29
2022
MintzRx — Pressure to Combat High Drug Prices Lands PBMs in the Hot Seat Mintz
May
14
2015
Employer’s Use of DNA Test to Catch Employee Engaging in Inappropriate Workplace Behavior Violates Federal Law Mintz
Jun
4
2015
Second Circuit Holds a Hard Switch Between Drugs Is an Unlawful Product Hop Under Section 2 Mintz
Jun
29
2015
Rocky Mountain High Part II: Colorado’s Highest Court Approves Employer’s Stance that Employee Toke is No Joke Mintz
Nov
14
2019
CMS Ignores the Courts: 2020 Hospital Outpatient Prospective Payment System Final Rule Includes 340B Rate Cuts Already Ruled Unlawful Mintz
Dec
14
2015
FDA Legal and Regulatory – 2015 Year In Review Mintz
Feb
5
2016
Behind the Curtain: Shkreli was NOT the Big Story on the Hill Today Mintz
Jun
7
2023
FDA Requests Public Input on Increasing Access to Home-Use Health Technologies Mintz
Jan
28
2020
FDA User Fees: How Do They Work? Mintz
Mar
24
2016
Federal Circuit Finds Personal Jurisdiction over Mylan in Two Hatch-Waxman Appeals Mintz
Apr
4
2016
FDA Differentiates Biosimilar Labeling from Generic Drug Labeling Mintz
Apr
6
2020
U.S. Department of Justice Issues First COVID-19-Related Business Review Letter to Medical Supplies Distributors Mintz
Oct
23
2023
OCR Cybersecurity Newsletter Emphasizes Significance of HIPAA Sanction Policies Mintz
Sep
1
2016
FDA Announces Dates for Long-Awaited Public Hearing on Its Regulation of Off-Label Communications Mintz
Dec
20
2023
2023: Another Year Chock Full of Challenges for FDA Mintz
Aug
7
2020
CMS Proposes Additional Cuts to Part B Reimbursement of 340B Drugs Mintz
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins